Material
T oll-like receptors are a family of pattern recognition receptors that sense highly conserved structures from microorganisms (1) . Among the TLR family, TLR9 recognizes the DNA sugar backbone 2Јdeoxyribose of hypomethylated CpG oligodeoxynucleotides (CpG ODNs) 3 from invasive bacteria and from autologous DNA of patients who suffer from systemic lupus erythematosus (2) (3) (4) . CpG ODNs represent a potent activator of the immune system (5, 6) . TLR9 activation in immune cells induces a cascade of events aimed at the elimination of the pathogen; TLR9 agonists activate plasmacytoid dendritic cells to secrete type I IFN and to fully mature into APCs (7) . As a result, activation of innate immune effectors such as NK cells and expansion of CTLs is obtained. Additionally, CpG ODNs can generate humoral immune responses by the induction of polyclonal B cell proliferation and Ig synthesis (8) . This immune cascade has prompted the development of synthetic TLR9 ligands that could be used to enhance the immune response in a tumor environment, which could translate into a clinical benefit for patients with cancer. Indeed, TLR9 agonists are currently being evaluated as an adjuvant in many clinical trials of solid cancer (colon cancer, breast cancer, melanoma, non-small cell lung cancer, glioblastoma) and hematological malignancies (B cell chronic lymphocytic leukemia, nonHodgkin's lymphoma) (9) .
However, although TLR expression was initially thought to be restricted to the cells of the immune system, recent studies suggest that many different tumor cell types express TLR9 and that TLR9 signaling promotes tumor growth, survival, and immune evasion (10) . B cell neoplasms such as multiple myeloma (MM; a plasma cell malignancy), lymphocytic leukemia, and lymphomas mirror their normal precursors and respond to TLR9 ligands (8) . Indeed, CpG ODNs can promote both MM cell proliferation and drug resistance through an autocrine secretion of IL-6, as well as proliferation of B cell chronic lymphocytic leukemia cells from patients either with progressive diseases or bearing unmutated Ig variable H chain genes (11) (12) (13) . Additionally, many solid tumor cell types do express TLR9 and are responsive to CpG ODNs (e.g., colon, prostate, breast, melanoma, lung) (14) .
TLR signaling induces Erk1/2 MAP kinase and NF-B activation in MM and colon cells that could contribute to malignant transformation (15) . NF-B activation, either through mutations or interactions with the microenvironment, has been involved in the progression of many cancers, including MM (16). As we previously published, resistance of MM cells to TRAIL can occur through the activation of the NF-B pathway (17) . TRAIL is a member of the TNF ligand superfamily, expressed and used by immune effector cells such as NK, NKT, and CD8 T cells to eliminate tumor cells (18) . TRAIL induces the death of cancer cells but spares normal cells; therefore, TRAIL-induced apoptosis could be involved in the immune surveillance of cancers (19) . Furthermore, TRAIL resistance has been observed in many cancer cell types and various mechanisms including translocation of NF-B, and activation of PKB/Akt or Erk MAPK seem to be involved (17, 20, 21) . These pathways can be induced by TLRs, including TLR9 (22) (23) (24) , therefore jeopardizing the efficiency of the therapeutic use of TLR9 ligands. The aim of this work was to study the effects of CpG ODNs on TRAIL-induced cell death of tumors by using MM, colon, and breast cancer cell lines.
Materials and Methods

Human myeloma cell lines (HMCLs), colon cancer cell lines, and breast cancer cell lines
The HMCL named MDN has been established in our laboratory and is cultured in the presence of 3 ng/ml rIL-6 (Novartis Pharmaceuticals). The KMM1 HMCL was provided by Dr. T. Otsuki (Okayama, Japan) and the Karpas 620 cell line by Dr. A. Karpas (Cambridge, U.K.). The MM.1S HMCL was provided by Dr. S. T. Rosen (Chicago, IL). NCI-H929 was purchased from Deutsche Sammlung von Mikroorganismen and Zelkulturen. C45 was established in our laboratory from an ascites of a stage IV colon cancer patient. The colon cancer cell line Colo205 and the breast cancer cell line HCC1569 were obtained from the American Type Culture Collection. Cal51 was provided by Dr. J.-L.Merlin (Nancy, France). All cell lines were maintained in RPMI 1640 medium supplemented with 5% FCS, 2 mM glutamine, and antibiotics.
RNA isolation and RT-PCR
Total RNA was extracted, treated by DNase, and reverse transcribed as previously described (11) . cDNA concentration was quantified by a spectrophotometer (NanoDrop) before amplification by PCR (35 cycles) using the following specific primers for TLR9 (Sigma-Genosys): 5Ј-TTATGGACTTCC TGCTGGAGGTGC-3Ј and 5Ј-CTGCGTTTTGTCGAAGACCA-3Ј.
Cell viability assay
Cell lines (10 5 cells/200 l) were cultured with or without mapatumumab, lexatumumab, recombinant human TRAIL, or agonist Fas Ab for 48 h in the presence or absence of CpG ODN. Cell viability was determined with PE-conjugated Apo2.7 labeling and analyzed on a FACSCalibur flow cytometer (BD Biosciences).
Western Blotting
Cells (10 6 cells/ml) were serum-starved for 18 h, treated or not, harvested, and resuspended in lysis buffer (10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 5 mM EDTA, 1 mM PMSF, 2 mM Na 3 VO 4 ,1 mM NaF, 2 g/ml aprotinin, 1 g/ml leupeptin, and 0.5% Nonidet P-40). Protein concentration was measured by using bicinchoninic acid (BCA protein assay; Pierce) and 90 g was separated by 10% SDS-PAGE and electrotransferred to polyvinylidene difluoride membranes. Signals were detected by standard techniques using ECL detection (Roche).
Abs, cytokines, and reagents
Human TRAIL-R1 or -R2 agonist mapatumumab and lexatumumab mAbs, respectively, were provided by Human Genome Sciences. Recombinant human TRAIL and recombinant TRAIL receptors DR4 and DR5 were purchased from R&D Systems. mAb CD95 (FAS clone CH11) was purchased from Beckman Coulter. mAbs against caspase-8, phospho-IB␣ Ser 32/36 (5A5), and IB␣ were from Cell Signaling Technology; actin was from Chemicon International. U0126 and Bay11-7082 were purchased from Alexis. CpG ODNs were provided by Invitrogen. Bases shown in uppercase letters are phosphodiester and those in lowercase letters are phosphorothioate (nuclease resistant): the ODN 2006 sequence was 5Ј-tcgtcgttttgtcgttttgtcgtt-3Ј, the all-phosphodiester ODN 2006-G5 sequence was 5Ј-TCGTCGTTTTGTCGTTTTGTCGTTGGGGG-3Ј, and the TLR9 inhibitory ODN sequence was 5Ј-tttagggttagggttagggttaggg-3Ј.
Surface plasmon resonance (SPR)
Experiments were conducted at 25°C on a BIAcore 3000 instrument. For binding analysis, either 200 resonance units of DR4 and DR5, 2000 resonance units of recombinant TRAIL, or 8000 resonance units of lexatumumab were covalently coupled to a research grade CM5 chip (GE Healthcare) by amine coupling as recommended by the manufacturer. All measurements were baseline-corrected by subtracting the values obtained from the analyte being injected over a control flow cell. Binding of mapatumumab (3 g/ml), lexatumumab (3 g/ml), or recombinant TRAIL (2 g/ml) either alone or preincubated for 60 min with CpG ODN (0.78 -12.5 g/ml) was assayed for 2 min at a flow rate of 40 l/min on DR4-or DR5-immobilized chips. Dissociation was monitored for 3 min and then the surface was regenerated by injection of 10 mM glycine (pH 2.0). Measurement of the direct binding of CpG ODN to recombinant TRAIL-immobilized or lexatumumab-immobilized chips was performed as follows. Five concentrations of CpG ODN ranging from 3.25 to 52 nM for CpG ODN injected over a LexA-immobilized chip and from 103 nM to 3.3 M for CpG ODN injected over a recombinant TRAIL-immobilized chip were titrated from low to high concentrations in a single-cycle mode for 3 min at 40 l/min. Dissociation was monitored for 4 min. Data were analyzed using the BiaEval 4.1 software (Biacore).
NK cell expansion and cytotoxic assays
Assessment of NK cell expansion was performed as previously described (25) . Briefly, PBMCs from normal volunteers were purified by FicollHypaque centrifugation and cocultured with irradiated EBV-transformed B lymphoblastoid cells in 8% human serum and in the presence of IL-2 for 4 -6 wk. The proportion of CD3 Ϫ /CD16 ϩ NK cells increased to Ͼ50% during the culture. Expanded CD3 Ϫ /CD16 ϩ NK cells were then purified using anti-CD16 microbeads (Miltenyi Biotec) and the cytotoxic assay was performed.
51 Cr-labeled target cells were incubated for 15 min with CpG ODN, and cytotoxic assays were performed in 96-well V-bottom plates with 3000 51 Cr-labeled target cells in 200 l (4 h). The percentage of specific cytotoxicity was determined as follows: (experimental release Ϫ spontaneous release)/(total release Ϫ spontaneous release) ϫ 100.
Results
CpG ODN inhibits the apoptosis of HMCLs induced by TRAIL through DR5
We first determined the expression of TLR9 on a panel of six representative HMCLs. As shown in Fig. 1 , we detected TLR9 at various levels in the HMCLs KARPAS 620, MDN, NCI-H929, NAN6, and KMM1, but not in MM1S. Incubation of KARPAS 620, MDN, and KMM1 with CpG ODN did not modify the apoptosis induced by 50 ng/ml human recombinant TRAIL. On the contrary, CpG ODN decreased the apoptosis of NCI-H929, NAN6, and, more surprisingly, TLR9-negative MM1S cells (mean of reduction, 53 Ϯ 3, 84 Ϯ 6, and 62 Ϯ 12%, respectively) (see Fig. 2A and Table I ). The effect of CpG ODN on TRAIL-induced apoptosis was dose dependent as shown in Fig. 2B , and the inhibition of apoptosis was obtained over a wide range of TRAIL concentrations as shown in Fig. 2C for NCI-H929. It is known that TRAIL induces apoptosis through the activation of two receptors, TRAIL-R1 (DR4) and/or TRAIL-R2 (DR5). To better characterize the mechanism of apoptosis inhibition observed with CpG ODN, we replaced human recombinant TRAIL with mapatumumab and lexatumumab, two agonist Abs directed against DR4 or DR5, respectively (26, 27) . As summarized in Table I for all six HMCLs and illustrated in Fig. 3A , HMCLs were either solely sensitive through DR4 (KARPAS 620), DR5 (NCI-H929, NAN6, and MM1S), or both (MDN, KMM1). Strikingly, CpG ODN completely blocked the apoptosis induced by lexatumumab in MDN, NCI-H929, KMM1, NAN6, and MM1S, but not that induced by mapatumumab. The effect of CpG ODN on DR5-induced apoptosis was dose dependent, as shown in Fig. 3B . No inhibition of mapatumumab-induced apoptosis was observed in MDN even at suboptimal concentrations of Ab (Fig. 3C ). As shown in Fig. 3D , the cleavage of caspase-8 in NCI-H929 induced by lexatumumab was blocked by the addition of CpG ODN to the culture. This result suggested that CpG ODN could act at the initiation of the cell death signaling pathway.
As Fas is a member of the TNF ligand superfamily that also induces apoptosis of tumor cells, we wondered whether CpG ODN could also inhibit its function. NCI-H929 was Fas-resistant, but KMM1 and MDN were Fas-sensitive ( Fig. 3E and data not shown). Stimulation of KMM1 or MDN by an anti-Fas mAb agonist induced a dose-dependent apoptosis that was not inhibited by CpG ODN. Taken together, our results suggested that CpG ODN specifically inhibited TRAIL-induced apoptosis through DR5.
CpG ODN inhibits the apoptosis of colon and breast cancer cell lines induced by TRAIL through DR5
As CpG ODNs are intended for use in both solid and hematologic cancer patients, we also performed the experiment on two colon cancer cell lines, C45 and Colo205 (Fig. 4) , and two breast cancer cell lines, HCC1569 and Cal51 (data not shown). Both colon cancer cell lines express TLR9 (Fig. 4A) , and CpG ODN decreased the apoptosis of the Colo205 line induced by recombinant human TRAIL (mean of reduction, 60 Ϯ 14%). The colon and breast cancer cell lines were only sensitive to DR5 stimulation. As illustrated in Fig. 4B for Colo205, addition of CpG ODN decreased the lexatumumab-induced apoptosis, either partially in Colo205, C45, and HCC1569 (mean of reduction, 47 Ϯ 15%, n ϭ 3; 60%, n ϭ 2; and 74%, n ϭ 2, respectively) or completely in Cal51 (mean of reduction, 97%, n ϭ 2).
The blocking of lexatumumab-induced apoptosis depends on the phosphorothioate modification of CpG ODN
Synthetic CpG ODNs that are currently used in vitro and in clinical investigations bear a nuclease-resistant phosphorothioate backbone that increases their half-life. In contrast, the phosphodiester a TLR9 expression was determined by PCR. Survival of six HMCLs in the presence of rhTRAIL (50 ng/ml), mapatumumab, or lexatumumab (6g/mL) was determined by Apo2.7 staining at day 2. The mean values Ϯ SD of three independent experiments are shown. rhTRAIL, recombinant human TRAIL.
bond of native DNA is highly sensitive to degradation by endonucleases. Both forms of CpG ODNs stimulate TLR9 and induce immunostimulatory activities. To determine whether the native form of CpG ODN was as potent as the synthetic form in the inhibition of apoptosis, we measured the TRAIL-induced apoptosis in the presence of either phosphorothioate-modified CpG ODN (CpG 2006) or a synthetic phosphodiester CpG ODN (CpG 2006-G5). The later sequence had a higher capacity to be internalized and to stimulate TLR9 than did native CpG ODN due to the addition of a 3Ј poly-G string. As shown in Fig. 5 , the phosphodiester CpG ODN did not inhibit the lexatumumab-induced apoptosis, suggesting that the protection was TLR9-independent. Furthermore, addition of a non-CpG ODN sequence designed to compete with the binding of CpG ODN 2006 to its receptor and that lacks TLR9 stimulatory capacity totally abrogated the apoptosis. As this CpG ODN also has a phosphorothioate backbone, our data suggest that the protection of tumors cells against TRAIL depends on the phosphorothioate modification of CpG ODN rather than on TLR9 stimulation. 
Phosphorothioate-modified CpG ODN inhibits the binding of lexatumumab to DR5
It has been previously shown that the internalization of DR4 and DR5 occurs within minutes of TRAIL binding (28) . In agreement, we observed a decrease of DR5 cell surface staining in the presence of lexatumumab (data not shown). Surprisingly, the addition of phosphorothioate-modified CpG ODN blocked the disappearance of DR5 from the cell surface. This result suggested that phosphorothioate-modified CpG ODN could perturb the interaction of TRAIL or anti-DR4/DR5 mAbs with their respective receptors in a TLR9-independent manner.
To test this hypothesis, we immobilized recombinant DR4 or DR5 on an SPR chip surface and observed the binding of either mapatumumab or lexatumumab, respectively, in the presence or absence of CpG ODN. DR4 and DR5 formed a saturated complex with mapatumumab and lexatumumab mAbs, respectively (Figs. 6,  A and B) . In agreement with our hypothesis, incubation of phosphorothioate-modified CpG ODN with DR5 (Fig. 6A ), but not with DR4 (Fig. 6B) , inhibits the interaction with the corresponding Ab in a dose-dependent manner. Furthermore, the binding of recombinant TRAIL to DR5 was also inhibited by phosphorothioatemodified CpG ODN in a dose-dependent manner (Fig. 6C) . Conversely, phosphodiester CpG ODN did not inhibit these interactions (supplemental Fig. S1 ). 4 Taken together, these results suggested that phosphorothioatemodified CpG ODN could directly bind to DR5, recombinant human TRAIL, or lexatumumab. Surprisingly, no direct binding of CpG ODNs to DR5 was observed (data not shown). In contrast, we observed binding of CpG ODNs to lexatumumab when it was immobilized on an SRP chip surface, but not to mapatumumab (Fig.  6D) . Similarly, binding of CpG ODNs to recombinant human TRAIL immobilized on an SRP chip surface was also observed (Fig. 6E) .
Phosphorothioate-modified CpG ODN inhibits the killing of DR5-sensitive tumor cells by NK cells
TRAIL is expressed and used by immune effector cells such as NK, NKT, and CD8 T cells to eliminate infected cells, tumor cells, or autoreactive cells (18) . As NK cells have been reported to be involved in the immune surveillance of cancer, we wondered if CpG ODN could alter their cytotoxicity toward tumor cells. To this end, we incubated NCI-H929 with or without a phosphorothioatemodified CpG ODN and then measured the cytotoxicity induced by NK cells. As shown in Fig. 7A , the lysis of NCI-H929 by NK cells was significantly reduced in the presence of CpG ODN (mean of lysis reduction at an E:T ratio of 1:15, 45 Ϯ 23%, n ϭ 3). A similar result was obtained for another DR5-sensitive cell line (Colo205) but not with the doubly DR4-and DR5-sensitive MDN cell line (data not shown). Finally, neutralization of TRAIL on NK cells by a blocking Ab partially decreased the cytotoxicity of NK cells to the same level as that obtained upon CpG ODN incubation (mean of lysis reduction at E:T ratio of 1:15, 49 Ϯ 1%, n ϭ 3; Fig. 7B ). These data suggested that the component of NK cell cytotoxicity involving TRAIL was inhibited by CpG ODN.
Discussion
TLRs are expressed by cells of the immune system, as well as by tumor cells of various origins. Although biological consequences of TLR activation have been extensively studied in immune cells, the effect on cancer cells is largely unknown. In the present study, we aimed to determine the effect of CpG ODN on the TRAILinduced cell death of cancer cells. We show that a synthetic phosphorothioate-modified CpG ODN inhibits the killing of various DR5-sensitive tumor cells through a TLR9-independent binding to TRAIL or to lexatumumab. This inhibition reduces the cytotoxic activity of NK cells through TRAIL and could therefore dampen the clinical efficacy of CpG ODN-based adjuvants.
Although synthetic CpG ODN sequences have been widely used in vitro to decipher the TLR9 signaling pathway and to stimulate the immune system, their exact mechanism of action has only been recently uncovered (2, 29) . Indeed, TLR9 recognizes natural phosphodiester DNA through the DNA sugar backbone 2Ј-deoxyribose rather than through CpG motifs, as thought so far. In contrast, phosphorothioate-modified synthetic ODNs, despite strong binding, are dependent on CpG motifs to activate TLR9. Our results extend the structure-dependent function of phosphorothioate-modified ODNs in the cell death pathway.
So far, known effects of CpG ODN on cell death resistance have involved TLR9 stimulation and Erk1/2 or NF-B signaling pathway activation. Additionally, it has been shown that NF-B activation contributed to LPS/TLR4-induced apoptosis resistance of lung cancer cells against TRAIL (30) . We also observed NF-B activation through phosphorylation of IB in the presence of CpG ODN; however, inhibition of either NF-B or Erk1/2 activation by specific inhibitors did not reverse the effects of CpG ODNs (supplemental Fig.  S2 ). Therefore, the survival effect was not mediated by these previously described pathways. On the contrary, despite activation of TLR9 signaling by classical synthetic CpG ODNs, the mechanism of survival was TLR9-independent, as it was also observed in a TLR9 Ϫ cell line and with a sequence designed to act as an antagonist of TLR9. Furthermore, we showed that the phosphorothioate modification of the CpG ODN, necessary for the nuclease resistance of the sequence, conferred the inhibitory capacity. In agreement with this finding, it has been previously shown that the phosphorothioate backbone of ODN sequences strongly increased nonspecific binding to various proteins. In particular, phosphorothioate sequences inhibit basic fibroblast growth factor binding to its receptor (31, 32) . This stickiness of phosphorothioate sequences is also observed in the binding to TLR9, as a phosphorothioate-modified sequence, regardless of the bases, has a higher TLR9 affinity than does the same phosphodiester sequence (29) . Taken together, these data imply that natural DNA sequences from bacteria would trigger TLR9 signaling in tumors and immune cells, leading to activation. On the other hand, synthetic phosphorothioate CpG ODNs would both mediate the previous effects and induce TLR9-independent phenomena such as receptor-ligand 4 The online version of this article contains supplemental material. binding inhibition. This phenomenon could be extended to the inhibition of virus entry, as it has been recently shown that human cytomegalovirus, hepatitis C virus, and HIV entry are blocked by phosphorothioate-modified ODNs, regardless of CpG motifs (33) (34) (35) (36) . One could therefore take advantage of this to design antiviral vaccines that target virus entry. Phosphorothioate-modified CpG ODN inhibits the killing of the HMCL NCI-H929 by NK cells. A, Cytotoxicity of NK cells against NCI-H929 in the absence or presence of 5 g/ml CpG ODN. Data shown are means Ϯ SD of one experiment performed in triplicate and are representative of three independent experiments. B, Cytotoxicity of NK cells against NCI-H929 was determined in the presence of 5 g/ml CpG ODN, 5 g/ml azide-free TRAIL-neutralizing Ab, or an isotype control Ab. Data shown are means Ϯ SD of one experiment performed in triplicate and are representative of three independent experiments. Given our present finding, it is likely that the capacity of phosphorothioate CpG ODNs to inhibit TRAIL-induced apoptosis could have an influence on the outcome of previously published studies. Therefore, interpretation of experiments should be done with caution and would better be completed with phosphodiester sequences stabilized by 3Ј poly-G extensions that confer a nanoparticle-like structure (37) .
Regarding the inhibition of TRAIL-induced apoptosis, we observed a decrease in the cytotoxicity mediated by NK cells. This result suggests that cells of the immune system could be partially dampened in their function of tumor surveillance, particularly in the case of CpG peritumoral injection. Fortunately, note that the lysis machinery of immune effector cells is not restricted to TRAIL and therefore could be protected from a major shutdown.
In conclusion, our results confirm the need for an encapsulation of CpG ODNs that would avoid unspecific binding with unexpected consequences. Finally, these data increase our understanding of the function of CpG ODNs in tumors.
